Tirzepatide + B12 / Glycine (Compounded Tirzepatide)

'Tirzepatide with B12' is how much compounded tirzepatide is now sold. A state-licensed (503A) compounding pharmacy puts tirzepatide in a multi-dose vial with cyanocobalamin (vitamin B12), or sometimes methylcobalamin, and some versions add glycine, niacinamide (vitamin B3), or pyridoxine (B6). Telehealth companies, med spas, and weight-loss clinics then prescribe it. Additives are now the norm rather than a niche. A secret-shopper study of 75 weight-loss clinics and med spas in two states (August–October 2025) found that 56% offered compounded GLP-1 products combined with B vitamins. The stated reason is nutritional. Tirzepatide cuts appetite and food intake sharply, and the argument is that B12 protects against deficiency and supports energy during a large calorie deficit. Glycine is pitched as 'metabolic support'. These are real concerns in principle. B12 deficiency is a recognized risk after stomach or bowel surgery (including bariatric surgery), with inflammatory bowel disease, long-term metformin or acid-suppressing drugs, a vegan diet, and older age. But screening isn't recommended for average-risk adults, and there is no trial showing that adding B12 to tirzepatide improves any outcome, and the dose of B12 in each shot depends on the vial's concentration and on your tirzepatide dose. It goes up and down with the drug, which is not how anyone would design B12 replacement. The main reason the additives exist is regulatory. Federal law (section 503A of the FD&C Act) bars pharmacies from compounding 'regularly or in inordinate amounts' drugs that are 'essentially copies' of a commercially available FDA-approved product. The exception is a change the prescriber determines makes a 'significant difference' for an identified patient. While tirzepatide was on FDA's drug shortage list, that limit didn't bite. FDA's final determination that the shortage was resolved came on December 19, 2024, after it re-examined its first October 2024 decision. Enforcement discretion then ended on February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B outsourcing facilities. After that, plain compounded tirzepatide had no legal cover, and adding an ingredient became the most common way to argue that a product is different from Zepbound. FDA has now rejected that argument directly (see Considerations).

Tirzepatide is a single 39-amino-acid peptide that activates two incretin receptors: GIP and GLP-1. It reduces appetite and food reward through brain and vagal pathways, slows stomach emptying, increases glucose-dependent insulin release, and lowers glucagon. Those effects produced roughly 20% average weight loss at the 15 mg dose in the SURMOUNT program. Vitamin B12 is a cofactor for two enzymes: methionine synthase (needed for DNA synthesis and red blood cell formation) and methylmalonyl-CoA mutase (needed for energy metabolism and nerve health). Absorbing B12 from food depends on adequate stomach acid and intrinsic factor. The theoretical concern with tirzepatide is mainly lower intake: people eat less, and some eat less meat, eggs, and dairy. Whether that translates into measurable B12 deficiency on tirzepatide hasn't been studied, because the trials didn't routinely check vitamin levels. There is no pharmacological synergy. B12 does not increase tirzepatide's weight loss, and tirzepatide does not need B12 to work. B12 also does not raise energy in people who aren't deficient. Glycine, niacinamide, and B6 at the amounts present in a weekly injection have no demonstrated effect on weight, glycemia, or side effects. At best, the combination is a convenience: one injection that also delivers a small, variable dose of a vitamin. At worst, it is a mixture whose stability, compatibility, and sterility have not been characterized in published data, wrapped around a drug that works the same with or without the additive.

The tirzepatide half is backed by some of the strongest evidence in obesity medicine, for the branded product. SURMOUNT-1 (2,539 adults with obesity, 72 weeks) showed mean weight loss of 15.0%, 19.5%, and 20.9% at 5, 10, and 15 mg versus 3.1% with placebo. SURMOUNT-5, a head-to-head trial in 751 adults, found 20.2% weight loss with tirzepatide versus 13.7% with semaglutide at 72 weeks. Those results were generated with Lilly's FDA-approved product. Compounded tirzepatide has never been tested in a clinical trial, for bioequivalence or for outcomes. Its salt form, purity, and real concentration can differ from the branded drug and from one pharmacy to another. The B12 half has no combination evidence. No trial has compared tirzepatide with and without B12. The closest data is a 2026 post hoc analysis of SURMOUNT-1 through -4 (4,726 participants). It found vitamin-deficiency adverse events in 0.99% of tirzepatide-treated participants versus 1.07% on placebo, which is no signal. But vitamin levels were not routinely measured in those trials, so this shows an absence of data, not proof that tirzepatide never lowers B12. The general rationale for checking B12 in people at risk is standard medicine. The case for putting it in every tirzepatide vial is not. Glycine has small studies of its own on sleep and metabolic markers, none in combination with tirzepatide. Niacinamide and B6 have no tirzepatide-specific data at all. The post-shortage compounded market is the other part of the evidence picture. The same secret-shopper study that found B-vitamin combinations at 56% of clinics traced products to 23 compounding suppliers. Four of the 21 with available data were not licensed for sterile compounding, and three of 22 had recent state disciplinary actions. For the person injecting it, where the vial came from matters more than whether it contains B12.

Compounded tirzepatide products generally follow the Zepbound titration schedule. That means 2.5 mg once weekly for 4 weeks, then increases of 2.5 mg no sooner than every 4 weeks, up to a maintenance dose of 5, 10, or 15 mg weekly. Slow titration is the main tool for limiting nausea, vomiting, and constipation. The B12 (and any glycine or other additive) rides along in the same injection, so its dose rises with each tirzepatide step. With vs without B12: the tirzepatide does the work either way. If B12 is a real concern, the more defensible approach is to check a complete blood count and serum B12, plus methylmalonic acid if B12 is low-normal. If you're deficient, replete it separately with a dose chosen for you, independent of your tirzepatide dose. High-dose oral B12 (1–2 mg daily) works as well as injections for most people. People with risk factors (metformin for more than a few months, long-term acid suppressants, a vegan diet, older age, prior stomach or bariatric surgery, inflammatory bowel disease) should be checked regardless of which tirzepatide product they use. Compounded vials are dosed by volume, and concentrations differ between pharmacies and sometimes between refills. The same number of 'units' on an insulin syringe can be a different dose of tirzepatide. Confirm the dose in milligrams, not the syringe mark, with the prescriber at every change. All use should be managed by a qualified clinician with regular monitoring of weight, glucose, and GI tolerance.